Abstract: An electrode for an iontophoretic drug delivery system includes a retainer having a malleable characteristic. The retainer and a conductor are connected to a platform. The conductor and a dose controller are electrically coupled to the iontophoretic drug delivery system. A drug delivery matrix is operably connected to the platform and proximate the conductor wherein the conductor, the drug delivery matrix, and the dose controller cooperate to deliver a drug to a user when the electrode is affixed to the user and operably connected to the iontophoretic drug delivery system.

Abstract: An iontophoresis apparatus and method is disclosed that is suited to deliver a plurality of treatment methods such as, but not limited to, body site conductivity enhancement followed by low voltage iontophoresis.

Abstract: An iontophoresis apparatus and method is disclosed that is suited to deliver a plurality of treatment methods such as, but not limited to, body site conductivity enhancement followed by low voltage iontophoresis.

Abstract: A method for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular area having a neoplastic, angiogenic, fibroblastic, and/or immunosuppressive irregularity; providing a methotrexate based medicament, wherein the methotrexate based medicament is capable of inhibiting DNA synthesis; associating a therapeutically effective concentration of the inethotrexate based medicament with the affected ocular area of the living subject; and decreasing the neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularity of the living subject.

Abstract: A method for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular area having a neoplastic, angiogenic, fibroblastic, and/or immunosuppressive irregularity; providing a 5? fluorouracil based medicament, wherein the 5? fluorouracil based medicament is capable of inhibiting DNA synthesis; associating a therapeutically effective concentration of the 5? fluorouracil based medicament with the affected ocular area of the living subject; and decreasing the neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularity of the living subject.

Abstract: An iontophoretic apparatus comprising a housing member, a current distribution member, a medicament containment member and at least one of a lateral and medial straddling member. The straddling member are configured to correspond to the surrounding soft tissue.

Abstract: An iontophoretic drug delivery device storage apparatus and a method of using that device is disclosed. The device comprises a fluid reservoir, an electrode assembly and a tray apparatus. The fluid reservoir is capable of retaining a medicament and has a sealed fluid chamber defined by at least one seal. The seal includes a weaker region and a pinch-like configuration associated with that region such that application of pressure to the fluid reservoir breaks the weaker region of the seal, releasing the retained medicament. The electrode assembly comprises an active electrode, at least two passive electrodes a medicament carrying region, and a moat region around the medicament carrying region so that once fluid is delivered from the fluid reservoir to the electrode assembly the fluid is substantially retained in the medicament carrying means.

Abstract: The present invention is directed to a method and apparatus for an electrotherapeutic system including a first and second electrode. Each electrode includes a respective resistance wherein during operation of the electrotherapeutic system, an electrochemical reaction involving one or both of the electrodes varies the respective resistance of at least one of the electrodes.

Abstract: An iontophoretic drug delivery device storage apparatus and a method of using that device is disclosed. The device comprises a fluid reservoir, an electrode assembly and a tray apparatus. The fluid reservoir is capable of retaining a medicament and has a sealed fluid chamber defined by at least one seal. The seal includes a weaker region and a pinch-like configuration associated with that region such that application of pressure to the fluid reservoir breaks the weaker region of the seal, releasing the retained medicament. The electrode assembly comprises an active electrode, at least two passive electrodes a medicament carrying region, and a moat region around the medicament carrying region so that once fluid is delivered from the fluid reservoir to the electrode assembly the fluid is substantially retained in the medicament carrying means.

Abstract: An iontophoretic delivery device utilizing a polymeric gel matrix to ameliorate pH deviation within the device wherein the pH of the polymeric gel matrix is buffered at select pH ranges in order to reduce skin irritation. The polymeric gel matrix is housed within the iontophoretic delivery device as a buffering agent wherein the matrix provides a suitable physiological pH level above 4.0 and particularly the pH level deviates between approximately 4.1 to approximately 4.9, and preferably at the pH 4.5 for an effective operation of the iontophoretic delivery of a medicament to treat affected areas of a living subject's body.

Abstract: A method for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular area having a neoplastic, angiogenic, fibroblastic, and/or immunosuppressive irregularity; providing a methotrexate based medicament, wherein the methotrexate based medicament is capable of inhibiting DNA synthesis; associating a therapeutically effective concentration of the methotrexate based medicament with the affected ocular area of the living subject; and decreasing the neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularity of the living subject.

Abstract: A method for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular area having a neoplastic, angiogenic, fibroblastic, and/or immunosuppressive irregularity; providing a 5? fluorouracil based medicament, wherein the 5? fluorouracil based medicament is capable of inhibiting DNA synthesis; associating a therapeutically effective concentration of the 5? fluorouracil based medicament with the affected ocular area of the living subject; and decreasing the neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularity of the living subject.

Abstract: An iontophoretic power supply comprising hardware and software. The hardware includes means for interfacing with an iontophoretic output device; microprocessor means and a computer readable medium. The software is recorded on the computer readable medium and executable by the microprocessor means. The software is capable of performing the steps of facilitating the providing of at least one operating parameter by a user and applying the provided operating parameters to an interfaced iontophoretic device.

Abstract: An electrode for use in an iontophoretic drug delivery having a substantially uniform distribution of current about the electrode. One such electrode includes a substrate, at least one first conductive layer of material disposed upon the substrate and at least one dielectric layer of material disposed upon at least a portion of the at least one conductive layer of material. The dielectric layer cooperates with the conductive layer of material to promote the substantially uniform distribution of current. Another such electrode includes a substrate, a conductive layer of material and a sacrificial layer of material.

Abstract: The electrode comprises a) a layer (5) which conducts electricity for the supply or the collection of an electrical current traversing the electrode, and b) a consumable electrochemical interface layer (7). According to the invention, it comprises, in addition, an intermediate layer (6) made of a chemically inert and electrically resistant material. This layer can consist of a dispersion of fine particles of carbon in a polymer binder. Application in the preparation of electrodes with increased electrochemical capacity, for an ionophoresis device for the transdermal administration of drugs or a device for the electrocicatrization of wounds.

Abstract: An iontophoretic apparatus comprising a housing member, a current distribution member, a medicament containment member and a handle member. The current distribution member is associated with the housing member. The medicament containment member is associated with the current distribution member. The handle member is associated with the housing member. The handle member facilitates the positioning and placement of the iontophoretic apparatus.

Abstract: An ocular iontophoretic device for delivering an interferon to an affected area of a living being's eye comprising an active electrode assembly associated with a matrix, wherein the matrix includes an interferon capable of treating viral, immunoregulatory, and/or neovascularization conditions. A method for treating an affected area of a living being's eye comprising the steps of: associating an interferon with an ocular iontophoretic device; positioning at least a portion of the ocular iontophoretic device on the eye of a living being; and iontophoretically delivering the interferon to an affected area of the living being's eye.

Abstract: A connection system for an iontophoretic drug delivery apparatus comprises an electrode assembly, a power source and a structure for facilitating mating engagement therebetween. The electrode assembly includes a first interface and two electrical leads and the power source includes a second interface and two electrical contacts. The interfaces are configured to facilitate mating engagement therebetween and operative secured electrical continuity between the electrical leads of the electrode assembly and the electrical contacts of the power source.

Abstract: An ocular iontophoretic device for delivering an aptamer to an affected area of a living being's eye for inhibiting VEGF function therein, the device comprising an active electrode assembly associated with a matrix and/or reservoir, wherein the matrix and/or reservoir includes an aptamer capable of inhibiting VEGF function. A method for treating an affected area of a living being's eye, comprising the steps of: associating an aptamer with an ocular iontophoretic device; positioning at least a portion of an ocular iontophoretic device on the eye of the living being; and iontophoretically delivering the aptamer to an affected area of the living being's eye.

Abstract: A high current density iontophoretic device, comprising a reservoir, an applicator, an orientation maintaining member and an iontophoretic medicament administering member. The reservoir is capable of retaining medicament. The applicator is positionable upon a surface of an eye and includes at least one punctation therethrough. The at least one punctation is capable of being placed in fluid communication with each of the reservoir and at least one treatment area of an eye upon operative positioning of same. The orientation member substantially maintains the orientation of the applicator in the desired orientation upon operative positioning of same. The iontophoretic administering member serves to administer a medicament from the reservoir to the at least one punctation and, in turn, to a specific region of an eye of a patient.